Bibliographic Application
Navigating Global Regulations with Precision while Uncovering Drug Discovery through Expert Bibliographic Application
Navigating Global Regulations with Precision while Uncovering Drug Discovery through Expert Bibliographic Application
Ensuring international regulatory norms is crucial in the pharmaceutical sector, and bibliographic applications are vital in providing reliable and current information to support regulatory procedures.
Article 10a of Directive 2001/83/EC and Section 22(3)(1) of the German Medicines Act require submission of data for Modules 1 through 3. If a medicinal product’s active ingredients have been used for at least ten years in the Union with recognized efficacy and safety, pre-clinical and clinical trials can be replaced with specific references to published scientific literature. A comprehensive scientific bibliography covering all preclinical and clinical features is necessary for this evidence. For this purpose, this form of application is termed as bibliographical application.
The type of literature sources and content are crucial for a bibliographic application, as submitted work must be published by a reliable source and freely available in public domain. The data from own preclinical and clinical research may not be considered in the bibliographical application. Assessment reports, like EPAR for EU marketing authorizations or summary reports from competent authorities cannot be considered for transparency reasons. To establish the effectiveness and safety of a medical product, applicants must include both positive and negative literature data in their evidence and explain any missing information in a contentious manner.
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S Certification) is
Lipinski’s Rule of 5 (Ro5) is a crucial guideline in pharmaceutical development, helping researchers evaluate a compound’s likelihood of becoming an effective oral drug. However, with the rapid evolution of therapeutic strategies, it’s worth considering the relevance of Ro5 in the current drug design landscape. Understanding Lipinski’s Rule of 5
Regulatory affairs (RA) play a crucial role in the pharmaceutical industry; ensuring products meet quality, safety, and efficacy. As the industry grow further the need for qualified professionals to bridge gaps between companies and regulators increases. This blog explores Zenovel regulatory affairs expertise, our various facets, and valuable contribution to
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.